Jacob J, Stalmans I, Zeyen T
University Hospitals Leuven, Ophthalmology Campus St Raphael, Belgium.
Bull Soc Belge Ophtalmol. 2009(313):19-29.
To evaluate the clinical outcome of patients who received an Ahmed or Baerveldt implant for refractory glaucoma at the University Hospitals Leuven and to identify the factors which may influence the outcome.
Retrospective study including 62 eyes with uncontrolled glaucoma, who underwent the implantation of a drainage device between January 2002 and December 2008. Criteria for complete success were an intraocular pressure (IOP) < or = 21 mmHg and > 5 mmHg, and a minimum 20% decrease in IOP compared to baseline, without additional medications at 2 consecutive visits after 3 months. Qualified success was defined as the same criteria with additional medications. If these criteria were not met, if additional glaucoma surgery was needed, or if the eye became phtitic, the case was classified as failure. Other outcome measurements were IOP reduction, additional glaucoma medications at the last follow-up, visual acuity, visual field, and complications.
Over a mean follow-up period of 25 +/- 21,91 months, the mean intraocular pressure decreased from 27,98 +/- 6,5 mmHg to 15,2 +/- 5,87 mmHg (mean drop of 45%) at the last visit. Overall success (i.e. with or without medication) was 67.3%. Visual acuity improved or remained unchanged in 52/62 (83,9%) of patients. Eight patients (12,9%) had complications with significant visual loss (at least two Snellen lines worse) and five patients (8,1%) needed further surgery due to complications. No significant outcome predictors could be established.
Ahmed and Baerveldt implants are a safe and effective procedure for lowering the IOP in the management of refractory glaucoma.
评估在鲁汶大学医院接受艾哈迈德(Ahmed)或贝尔维尔德(Baerveldt)植入物治疗难治性青光眼患者的临床结果,并确定可能影响结果的因素。
回顾性研究纳入了2002年1月至2008年12月期间接受引流装置植入术的62例青光眼控制不佳的患者。完全成功的标准为眼压(IOP)≤21 mmHg且>5 mmHg,与基线相比眼压至少降低20%,在3个月后的连续2次随访中无需额外用药。合格成功定义为符合相同标准但需额外用药。如果未达到这些标准、需要额外的青光眼手术或眼睛发生眼球炎,则该病例归类为失败。其他结果指标包括眼压降低、最后一次随访时额外使用的青光眼药物、视力、视野和并发症。
平均随访期为25±21.91个月,最后一次随访时平均眼压从27.98±6.5 mmHg降至15.2±5.87 mmHg(平均降幅45%)。总体成功率(即无论是否用药)为67.3%。52/62例(83.9%)患者的视力改善或保持不变。8例患者(12.9%)出现并发症导致明显视力丧失(至少下降两行Snellen视力表),5例患者(8.1%)因并发症需要进一步手术。未发现显著的结果预测因素。
艾哈迈德和贝尔维尔德植入物是降低难治性青光眼眼压的安全有效方法。